羟萘酸沙美特罗（Salmeterol Xinafoate）.pdf

8 ADVAIR DISKUS (SALMETEROL XINAFOATE) 8.1 ADVAIR DISKUS AND THE ASTHMA this book, it is estimated that 210 million people currently AND COPD MARKETS suffer from COPD. More than 3 million people died from COPD in 2005 and projections are that the total number of Advair Diskus , also known as Seretide Accuhaler, is deaths from COPD will increase by 30% in the next 10 years a multidose dry powder inhaler containing the inhaled without intervention to reduce tobacco use.1 corticosteroid fluticasone propionate (100, 250, or 500 mg) The treatment goals for COPD are the prevention of and the long-acting b-agonist (LABA) salmeterol (50 mg) as disease progression, relief of symptoms, improvement the xinafoate salt (Figure 8.1). The combination of flutica- of exercise tolerance and health status, prevention and sone propionate (50, 125, 250 mg) and salmeterol (25 mg) as treatment of complications, prevention and treatment of the xinafoate salt is also available in a metered-dose hydro- exacerbations, and reduction of mortality.2 The B -agonists, 2 fluoroalkane inhaler (Seretide Evohaler). Serevent Diskus anticholinergics, theophylline, or combinations of these are is a multidose dry powder inhaler containing only the long- the first-tier treatment options. When these are inadequate, acting b-agonist salmeterol (50 mg) as the xinafoate salt. The the second-tier options are Advair Diskus or Symbicort . Diskus technology is a specially designed plastic inha